膀胱癌诊断与治疗的进展
膀胱癌仍是全球主要癌症死因之一,对患者生活质量、发病率、死亡率和医疗系统成本造成重大影响。非肌层浸润性膀胱癌经尿道膀胱肿瘤电切术后按风险分层行膀胱内辅助治疗,总生存率90%;肌层浸润性膀胱癌治愈率较低,但基因组学和肿瘤微环境研究推动了免疫检查点抑制剂、靶向治疗和抗体药物偶联物的应用。
要点
- 肉眼血尿常先于膀胱癌诊断出现。
- 非肌层浸润性膀胱癌初始行经尿道膀胱肿瘤电切术,随后按风险分层行膀胱内辅助治疗,总生存率90%。
- 肌层浸润性膀胱癌治愈率较低,但免疫检查点抑制剂、靶向治疗和抗体药物偶联物已应用于转移性疾病。
核心结论
- 膀胱癌仍是全球主要癌症死因之一,对患者生活质量、发病率、死亡率和医疗系统成本造成重大影响。
- 非肌层浸润性膀胱癌和肌层浸润性膀胱癌分组具有异质性,各有独特的病理和分子特征。
- 定义更好的选择标准以识别最可能从特定治疗中获益的患者是迫切需求。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 非肌层浸润性膀胱癌初始行经尿道膀胱肿瘤电切术,随后按风险分层行膀胱内辅助治疗,总生存率为90%。
- 肌层浸润性膀胱癌治愈率较低,原因涉及多种因素。
- 癌症基因组图谱项目识别了肌层浸润性膀胱癌的遗传驱动因素及管腔型和基底型分子亚型,其治疗反应不同。
- 对于非肌层浸润性膀胱癌,膀胱内免疫治疗(主要为卡介苗)是高危和高风险非肌层浸润性膀胱癌的金标准治疗,用于减少或预防初始经尿道膀胱肿瘤电切术后的复发和进展;新试验纳入免疫检查点抑制剂。
- 膀胱内基因治疗和联合膀胱内化疗近期已完成,结果有前景。
临床怎么用
- 对于局限性肌层浸润性膀胱癌,基本目标是改善膀胱切除术后或保留膀胱策略后的护理并降低发病率。
- 在转移性疾病中,对基因组景观和肿瘤微环境理解的进展已促成免疫检查点抑制剂、靶向治疗和抗体药物偶联物的实施。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bladder cancer remains a leading cause of cancer death worldwide and is associated with substantial impacts on patient quality of life, morbidity, mortality, and cost to the healthcare system. Gross hematuria frequently precedes the diagnosis of bladder cancer. Non-muscle-invasive bladder cancer (NMIBC) is managed initially with transurethral resection of a bladder tumor (TURBT), followed by a risk stratified approach to adjuvant intravesical therapy (IVe), and is associated with an overall survival of 90%. However, cure rates remain lower for muscle invasive bladder cancer (MIBC) owing to a variety of factors. NMIBC and MIBC groupings are heterogeneous and have unique pathological and molecular characteristics. Indeed, The Cancer Genome Atlas project identified genetic drivers and luminal and basal molecular subtypes of MIBC with distinct treatment responses. For NMIBC, IVe immunotherapy (primarily BCG) is the gold standard treatment for high grade and high risk NMIBC to reduce or prevent both recurrence and progression after initial TURBT; novel trials incorporate immune checkpoint inhibitors. IVe gene therapy and combination IVe chemotherapy have recently been completed, with promising results. For localized MIBC, essential goals are improving care and reducing morbidity following cystectomy or bladder preserving strategies. In metastatic disease, advances in understanding of the genomic landscape and tumor microenvironment have led to the implementation of immune checkpoint inhibitors, targeted treatments, and antibody-drug conjugates. Defining better selection criteria to identify the patients most likely to benefit from a specific treatment is an urgent need.
引用
- Lopez-Beltran A, Cookson MS, Guercio BJ, et al. Advances in diagnosis and treatment of bladder cancer. BMJ. 2024. PMID: 38346808. doi:10.1136/bmj-2023-076743
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。